Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ITS OK.
please delete.
thank you for your time.
Draw your own conclusion
I have been explained by my Chinese business associates in Asia regarding the significance of the info available to me
no pumping here no pimping there, and certainly I will not dump and sell. good luck .
just sharing the info that i just received yesterday.
i will post more tonight .
WE ARE GOING FOR THE RIDE OF OUR LIVES
Life is good at jbzyd or soon to be WXYZ or ABCD OR BOOM ?
Honestly...i dont know what it was written.
Just a bunch of emails from my buddies from asia.
I was briefly explained what it meant.
I m sure someone can read chinese and explain the article that came out from china yesterday.
Can someone who understand chinese pls translate.?
INFO 1 / 23
Draw your own conclusion
I have been explained by my Chinese business associates in Asia regarding the significance of this msg
no pumping here no pimping there, and certainly I will not dump and sell . good luck .
just sharing the info that i just received yesterday.
Life is good at jbzyd or soon to be WXYZ ?
11 / 12 of my otc stocks,,,are red....whats going on today?
News and some additional info coming. Just got a whole bunch of info via email from asia.
Downloading some of them now.
No pump pimp or dump here.
Just the facts.
Good day on jbzyd
It is our moment.
Getting real close N exciting.
Loves the volatility.
Thats makes it so much fun and enjoyable when investing on otc lala land.
This time we are going north.
Never under estimate the chinese.
They will surprise you in a good way and will often surpass your expectation. It is in their culture not to show any of their big guns until the timing is perfect.
Perfect execution and 100% bullseye sniper shot.
If you have done DD on wang's background, you will know we have the winner here.
GLTA
It seems that whenever there is an update and PR, OUR PPS either tanks or remains the same....
Its a tell tell sign. We will see another update this week.
Not pumping here.
Observe carefully...
News!boom!
https://finance.yahoo.com/news/adaptive-medias-partnership-cryptocurrency-pioneer-140500431.html
Company's Advisory Board Further Comprised of by Five Seasoned Executives from Industries Ranging from Investment Banking to High-End Celebrity Management LOS ANGELES, CA / ACCESSWIRE / April 9, 2018 / ...
Jbzyd is well and kicking.
Jbzy is expanding.
Recently posted Apr 4 2018 ads for employment
https://m.zhipin.com/gongsi/r660429.html?ka=company-jobs
Another post worth the time reading.
We have been here long enough.
Wang never dissapoints.
https://insiderfinancial.com/dolat-ventures-inc-otcmktsdolv-is-a-big-2017-winner-for-our-subscribers
Baxk to basic. Why invest in dolv ...jbzy....jbzyd
The fundamental basic of investing
: your own instincts.
"If every instinct you have is wrong, then the opposite would have to be right."
Looking forward for some spectacular news this coming week.
https://steemit.com/stocks/@acis/why-i-bought-all-the-usddolv-i-could
How often you see pinkie sjares on main stream news medias?
Cmt in kswo, phoenix
http://www.kswo.com/story/37877539/creative-medical-technology-holdings-announces-superior-immune-modulatory-of-amniostem-stem-cells-compared-to-other-stem-cell-types
Yes . I have read it.
It is not a paid advertising site or publication.
Its a serious news outlet for pharmaceutical and medical comminities/ readers.
CMT is gaining alot of exposure now.
News are spreading fast.
We have an unicorn in the making.
There are way too many possibilities for CMT.
Stem Cell Exosomes is definitely a positive outlook from CMT
WHY CELZ WILL DO EXTREMELY WELL
.
I will make it short.
On the most fundamental level, biotechnology is any technology or product developed using cellular and biomolecular processes from stem cell innovation to stem cell regeneration & rejenevation.
That means products as simple as bread and cheese could be considered biotech innovations — albeit very simple ones. Today, the biotech field has expanded substantially, and those involved in it are making significant strides towards solving some of the world’s greatest problems. ------» Creative Medical Technology (CMT)
In biotech field, we need
1-Innovation,
2-R&D ,
3-Patents and
4-Completion of all clinical phases 1,2,3,4
The above are the most important elements in securing success and ensuring its survival in medical sector.
CELZ has successfully completed all of the above and thriving in a very unique niche.
Why is it successful.?
1-Celz is innovative enough to adapt to its competitive and ever changing environment. Tim is
constantly delivering what the market expects and wants.--- stem cell procedures that can be applied on orthopedics, aesthetic, dentistry, reproductive, and many more areas.
2-Celz has gone through all the vigorous R&D to deliver positively on various treatments.
3- Celz has few patents under its belt to be the main revenue generators.
4-Celz has passed all 4 stages of clinical trials ...which is the most important and hardest hurdles in biotech industry.
Passing all clinical trials alone is a massive news already for celz.
Without the completion of such phases will only mean...game is over.
Tim and his team are doing great jobs to ensure celz is gaining medias exposure, eliminating all debts, marketing its patents and procedures to the consumers.
We are at the infant stage of celz. The ride has just started and rest assured this will be a very long ride.
Recently a very well known Nasdsq biotech firm failed its clinical stage 3 trial on aneurysmal subarachnoid hemorrhage. The market cap has diminished by 90%. The pps went from 15.5$ to 1.05$ ...a.drop by 90% after the failing phase 3 announcement.
Its a blessing to all of us , celz investors , to be at the right time, right place and the epic ride is coming anytime soon.
Know what you own.
What makes Celz different from other biotech firms?
Many investors on other biotech firms are buying on speculation and selling on celebration.
Celz has gone through all the obstables. Investors are not buying on speculation. We are done on speculation (clinical trials.)...been there and done that.
Celz Investors are buying and waiting to see how high the pps can go or possible buy out by big pharmas.
Remember ...a recent biotech firm which did not even pass stage 3, its pps was at 15.50 before it crashed down to 1.05$
We will not be looking at pennies or nickle here...but way beyond that. Sky is the limit. Because we have all the elements and we are starting to capitalize on a very unique market niche.
This is not a pump.
Certainly i am not pimping celz at all. Just research more about this field, you will agree with me.
To those who has left us, we thank you for your guidance. For those who are still on the journey , an epic ride is here.
Right here, right now
GLTA and God bless America and CMT.
5 MAIN MEMBERS OF CELZ.
EXCELLENT TEAM AND STRONG BACKGROUND IN SCIENCE & BUSINESS MANAGEMENT
THIS IS A WINNING TEAM. EAGER, AMBITIOUS AND TOP IN THE FIELDS.
Mr. Timothy Warbington-------CEO
Mr. Donald Dickerson----------CFO
Dr. Annette Marleau, PhD------SENIOR VP
Dr. Thomas E. Ichim, Ph.D.-----INDEPENDENT DIRECTOR
Dr. Amit N. Patel, M.D----------INDEPENDENT DIRECTOR
Mr. Timothy Warbington is President, Chief Executive Officer, Director of the Company. Mr. Warbington has served as a director and as Chief Executive Officer of CMT since February 2016 and has served as a director, Chief Executive Officer and President of Creative Medical Health since October 2011. He has over 25 years of executive level management experience. Mr. Warbington received a Bachelor’s Degree in Accounting from Arizona State University in 1984. From 1993 through 2007 he owned and operated a multi-million dollar national agricultural (produce). Prior to that, he served as Chief Operating Officer of the U.S. subsidiary of a British firm engaged in the international food trade. For eight years, Mr. Warbington has invested in the biotechnology industry and has provided strategic and tactical advice as a consultant to a publically traded bio-tech firm. In connection with this experience, he has built a network of scientists, physicians and executives to participate as executive officers and directors of Creative Medical Health.
Mr. Donald Dickerson is Chief Financial Officer, Senior Vice President, Director of the Company. Mr. Dickerson has served as a director and as Chief Financial Officer and Senior Vice-President of CMT since February 2016, and has served as a director and as Vice President and Chief Operating Officer of Creative Medical Health since June 2014. He received his Masters of Business Administration in Finance from the University of Southern California in May 2002. Mr. Dickerson has worked in a number of management and accounting positions and has experience with companies in the technology, manufacturing and health sciences area. From October 2003 until February 2009 he was employed as a vice-president for JP Morgan Chase in finance; from March 2009 until May 2014 he served as a director for GMT Ventures in finance and operations; and from June 2011 until May 2014 he also served as CFO for Medistem, Inc. in finance.
Dr. Annette Marleau, Ph.D. is Senior Vice President of the Company. Ms. Marleau has served as a Senior Vice-President of CMT since February 2016, and has served as Vice President and Chief Scientific Officer for Creative Medical Health since March 2014. Prior to joining Creative Medical Health, Dr. Marleau was the Director of Tumor Immunology at Aethlon Medical Inc. from 2011 until 2014. Dr. Marleau received her PhD in Immunology from the University of Western Ontario in 2004, received a MS in Reproductive Immunology from Ontario Veterinary Collateral, University of Guelph, Canada in 1999; and a BS in Biology from the University of Waterloo, Canada.
Dr. Thomas E. Ichim, Ph.D. is Independent Director of the Company. Dr. Ichim has served as a director and as President of CMT since February 2016, and has served as a director and Vice-President of Creative Medical Health, and as President of the Biotech Division, since October 2011. From 2007 until 2015 he served as Chief Science Officer, Chief Executive Officer, and President, and was a director, of MediStem Inc., a San Diego-based company engaged in development of endometrial regenerative cells which was acquired in 2014 by Intrexon Corporation for $26,000,000. From 2004 until 2007 he served as program manager for biorasi LLC, a clinical research organization. He also served as a director of Regen BioPHarma, Inc., a publicly traded biotechnology company, from 2012 until 2015. In 2005 Dr. Ichim received his PhD in Immunology from University of Sciences Arts and Technology, Olveston Monserrat; in 1999 he received a MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada; and in 1994 he received a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada.
Dr. Amit N. Patel, M.D. is Independent Director of the Company. Dr. Patel has served as a director of CMT since February 2016 and a director of Creative Medical Health since October 2011. He has been a practicing heart surgeon since 2008. Dr. Patel received his medical degree in 1998 from Case Western Reserve University, Cleveland, Ohio. He currently holds the following positions at the University of Utah; Associate Professor, Department of Surgery, Division of Cardiothoracic Surgery and Director Clinical Regenerative Medicine and Tissue Engineering. Dr. Patel has an MD from Case Western Reserve University. Dr. Patel is an accomplished inventor and has been the formulator of the Company’s Bionutraceutical® products. He is also a director of Jadi Cell LLC, a research facility located in Salt Lake City, Utah.
great news!
pls share with you about your caverstem experience.
i am sure many men will be interested in the procedure.
NO. DONT BE NAIVE, WE WILL NOT GO TO DOLLAR. SORRY
because celz would ALREADY be acquired or bought out by a big pharma prior reaching a dollar.
Yes, looking back most of the big pharma acquisition deals, most pharmas acquired the biotech when the pps was around 0.1 to 0.7 range.
CELZ has zero debt, liability or pending lawsuit and it certainly will attract some the attention of some big pharmas.
CMT DD COMPILATION
THE MORE WE KNOW, THE MORE WE LEARN ABOUT CMT
KNOW THE FACTS. BECAUSE YOU WILL INVEST MORE WISELY ON CMT.
THIS IS AN UNICORN IN THE MAKING
KNOW WHAT YOU OWN.
KNOWLEDGE IS POWER
PATENTS = KNOWLEDGE.= EPIC RIDE
-----> LETS THE POWER OF SCIENCE AND INNOVATION CHANGE OUR LIVES.<---------
LETS THE PARTY BEGINS.
Creative Medical Technology Holdings Announces Superior Immune Modulatory of AmnioStem Stem Cells Compared to other Stem Cell Types
April 4, 2018 • PR Newswire
Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem(TM) Procedure For Erectile Dysfunction At International Urology Conference
March 26, 2018 • PR Newswire
Thomas E. Ichim is now serving in a new position at Creative Medical Technology Holdings, Inc.
February 21, 2018 • RelSci Data Update
Creative Medical Technology Holdings Licenses Intellectual Property from Internationally Renowned Neurologist and Creates Neurology Focused Stem Cell Subsidiary
February 20, 2018 • PR Newswire
Stem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract Optimism
December 20, 2017 • PR Newswire
"Urologist to the Stars" Dr. Alexander Gershman Begins Treating Patients with Patented Caverstem(TM) Stem Cell Procedure for Drug Refractory Erectile Dysfunction
December 18, 2017 • PR Newswire
Creative Medical Technology Holdings Recruits Top Urologists for Caverstem(TM) Stem Cell Treatment of Erectile Dysfunction
December 14, 2017 • PR Newswire
Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction
October 19, 2017 • PR Newswire
Creative Medical Technology Holdings Expands Stem Cell Therapeutic Platform by Entry into Field of Stroke and Neurodegeneration
October 16, 2017 • PR Newswire
Developments in the Erectile Dysfunction Markets
August 28, 2017 • PR Newswire
Creative Medical Technology Holdings Achieves 100% Patient Enrollment in CaverstemTM Clinical Trial for Stem Cell Treatment of Erectile Dysfunction
August 28, 2017 • PR Newswire
Creative Medical Technology Holdings Demonstrates AmnioStem Derived Exosomes Inhibit Glioma Growth
July 25, 2017 • PR Newswire
Creative Medical Technology Holdings Adds Immune Modulatory Cells for Stimulation of Perispinal Angiogenesis to Induce Regeneration of Degenerated Discs
June 21, 2017 • PR Newswire
Creative Medical Technology Holdings Develops Platform Aimed at Augmenting All Mesenchymal Stem Cell Therapies for Lower Back Pain
June 7, 2017 • PR Newswire
Creative Medical Technology Holdings, Inc. Files Patent on AmnioStem(TM) Mediated Immune Reprogramming for Stroke
May 24, 2017 • PR Newswire
Creative Medical Technology Holdings to Expand into 10 Billion Dollar per Year Lower Back Pain Market with Acquisition of Issued US Stem Cell Patent---PATENT $$$$
May 18, 2017 • PR Newswire
US patent #9,598,673
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today the acquisition of issued US patent #9,598,673 covering use of various stem cells for treatment of lower back pain through healing of perfusion defects.
The Company believes, based on various scientific studies, that a large number of patients with lower back pain undergo progression to disc degeneration due to suboptimal levels of oxygen and nutrients entering the disc. This is believed to be a process similar to what happens in the heart, when the arteries feeding the heart thicken, resulting in reduced heart function. Thickening of arteries feeding the disc is believed to result in starving the disc of nutrients and oxygen, resulting in eventual deterioration and pain. Through administration of stem cells in proximity to the disc, the process is designed to stimulate production of new blood vessels, which will assist the disc to regenerate.
"Creative Medical Technology Holdings will develop this patent through the same process that we are using for our clinical-stage Caverstem procedure for erectile dysfunction," stated Timothy Warbington, President and Chief Executive Officer of the Company. "We plan to identify and engage key opinion leaders who will lead clinical trials, which will serve as the basis for accelerated commercialization."
The Company is currently running a clinical trial using autologous non-manipulated bone marrow stem cells for patients suffering from erectile dysfunction that are non-responsive to standard approaches such as Viagra. Once the trial is completed, the results will serve as the basis for marketing of disposables utilized in administration of stem cells.
"Although numerous companies are injecting stem cells directly into the disc, direct injection may only cause temporary benefit because the root cause of the pathology, in our opinion, is the reduced blood supply," stated Dr. Amit Patel, Director of Thoracic Surgery at University of Miami and co-founder of Creative Medical Technology Holdings. "By recreating in the microenvironment of the lower back the same thing that we do in atherosclerotic heart patients, we believe we have a novel way to treat this terrible condition that wreaks havoc on our health care system."
--------> THATS THE BIGGEST DIFFERENCE BETWEEN CMT AND OTHER ED BIOTECT FIRM
Several studies have shown that administration of stem cells possesses a therapeutic effect in cardiac conditions associated with poor circulation by stimulation of new blood vessel production, a process termed "angiogenesis". The current patent covers stimulation of angiogenesis in the lower back using mesenchymal stem cells. These cells can be used from the same patient, which is considered an "autologous therapy" as well as using stem cells in a universal donor manner, which is termed "allogeneic".
"The acquisition of this patent not only positions the company to expand into the disc degenerative space, but also provides a powerful platform for collaboration with other companies that are administering regenerative cells directly into the nucleus pulposus of the disc," commented Thomas Ichim, Ph.D., Chief Scientific Officer of the Company and inventor of the technology. "Stem cells are like seeds, they need to be planted into fertile soil. We feel that in certain patients it is essential to treat the lumbar ischemia, which is present in some patients suffering from disc degenerative disease, which will then allow the stem cells administered directly in the disc to perform their regenerative effects."
Creative Medical Technology Holdings Files Patent on Reducing Radiation Toxicity Using AmnioStem Universal Donor Stem Cell Product
April 4, 2017 • PR Newswire
Creative Medical Technology Holdings Appoints Internationally Renowned Stem Cell Pioneer Dr. Thomas Ichimas Chief Scientific Officer
March 8, 2017 • PR Newswire
Creative Medical Technology Holdings Announces Initiation of In House Research Program at San Diego BioLabs
February 22, 2017 • PR Newswire
Creative Medical Technology Holdings Files Patent on AmnioStem Stroke Therapy
December 13, 2016 • PR Newswire-------PATENT $$
filing of US patent application #62/400557 entitled "Treatment of Stroke by Amniotic Fluid Derived Stem Cell Conditioned Media and Products Derived Thereof."
The patent application covers the use of the Company's newly licensed AmnioStem stem cell as a production means for generation of nanoparticles termed "exosomes," which regenerate damaged brain tissue after stroke. The AmnioStem stem cell is subject to issued US patent #7,569,385 and was licensed exclusively from University of California San Diego ("UCSD").
"We are pleased at the successful fruits of this ongoing collaboration, which provides novel stem cell based therapeutic options by using products derived from stem cells as opposed to the stem cells themselves," said Amit Patel, MD, MSc, Head of Regenerative Medicine and Tissue Engineering at the University of Utah, and co-inventor of the patent.
The patent provides means of leveraging growth factors and nucleic acids generated by AmnioStem stem cells, in order to provide a "drug like" product that overcomes many of the hurdles associated with administration of stem cells.
"It is known that intravenous injection of stem cells usually results in accumulation in lungs, leading to reduced therapeutic efficacy. Concentrating and purifying regenerative factors produced by this unique stem cell type will accelerate development of this novel therapy, as well as develop combination therapies to provide the highest probability of success to patients suffering from this debilitating condition," said Santosh Kesari, MD, PhD Chair and Professor of Department of Translational Neurosciences and Neurotherapeutics at Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center in Santa Monica, CA.
"We are honored to have such an accomplished team which addresses problems from an unbiased and multidisciplinary perspective," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "By leveraging our intellectual, corporate, and developmental resources, we aim to accelerate finding treatments and potential cures for debilitating neurological disorders."
Creative Medical Technology Holdings Announces Creation of Amniotic Fluid Stem Cell Focused Subsidiary AmnioStem LLC
November 16, 2016 • PR Newswire
Creative Medical Technology Holdings, Inc. Recruits Internationally Renowned Urologic Surgery Pioneer Dr. Alexander Gershman to Scientific Advisory Board
November 1, 2016 • PR Newswire
Creative Medical Technology Holdings Expands Adult Stem Cell Therapeutic Platform to Combat Female Infertility Caused by Premature Ovarian Failure
August 24, 2016 • PR Newswire
Creative Medical Technologies Completes Proof-of-Concept Studies at Preventing Miscarriages Using Stem Cell Immunotherapy
June 21, 2016 • PR Newswire
OTC Markets Group Welcomes Newly Verified OTCQB Companies
June 20, 2016 • ENP Newswire
CMT ON WFMJ
This is just the beginning. The world is watching CMT now.
http://www.wfmj.com/story/37877539/creative-medical-technology-holdings-announces-superior-immune-modulatory-of-amniostem-stem-cells-compared-to-other-stem-cell-types
CMT on KLTV /ABC
News is spreading not just among the medical communities. it is also featuring on regular news outlet.
How often do you see OTC on regular news outlet?
http://www.kltv.com/story/37877539/creative-medical-technology-holdings-announces-superior-immune-modulatory-of-amniostem-stem-cells-compared-to-other-stem-cell-types
CREATIVE MEDICIAL ON VERDICT MEDICAL NETWORK.
Creative Medical Technology Holdings reveals stem cell product success
The huge news from celz is spreading not just pertain to usa but around the world, especially among the medical communities.
Recent publication regarding creative medical is gaining world wide attention.
Please note, verdict network is produced by a non biased experienced team with a strong background in B2B publishing and delivered to a global audience of decision-makers through expansive industry network. Many big pharmas latest iinovation and patents are published on verdict.
THE BIG BOYS IN PHARMAS AND VC ARE NOTICING CREATIVE MED NOW.
KNOW WHAT YOU OWN.
ENJOY YOUR EPIC RIDE.
https://www.medicaldevice-network.com/news/creative-medical-technology-holdings-reveals-stem-cell-product-success/
WOW....Whats happening?
is it like abvg on special sales now?
mega sell off and trades on 1s. ...almost 355m
It is better for all of us. The PPS is gradually, slowly going up.
No sudden big euphoria jump, no kamikaze dive.
In the long run, the PPS will go up much higher from today.
The potential is huge., the wheels are in motion. Celz is going according to plan.
NO over-inflating boastful PR, No BS update.
THE TELL TELL SIGN IS EVERYWHERE.
WE WILL HAVE ANOTHER UPDATE NEXT WEEK.
YES. FOLKS.
THE HINT IS OUT THERE. STRONG HINT.
NO PUMPING HERE.
CERTAINLY NO PIMPING HERE
KNOW WHAT YOU OWN.
ENJOY THE RIDE OF YOUR LIFE.
4s wall is cracking.
will see total collapse anytime soon?
Knowing that all the shares are pretty much locked up.
Shares are extremely scarce n hard to come by.
Know what you own.
Jbzyd is golden here.
These are all big players...such as Allergan, astral, Bayer, hologic, alma, etc
Many multi national boys here.
Expect some big positive feedback from the conference.
ENJOY THE RIDE.
GO $$$CELZ$$$$
yes,,, i know.
will be really lucky if i can sell at 1s....it seems everyone is buying at 1s now except me at 2s
wow...it seems like it is a biz that is mainly selling shares.
bad investment for me for now....holding over 15m @ 2s
at this rate,,,we won't even can pass 3s.
Something is brewing.
Someone is loading a lot of shares.
Go $$$$rcgr$$$$